CCL18/PARC RNAi Summary
Homo sapiens chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) (CCL18), mRNA
This RNAi causes protein knockdown.
Packaging, Storage & Formulations
Store at -20C. Avoid freeze-thaw cycles.
This product is produced by and distributed for Abnova, a company based in Taiwan.
Alternate Names for CCL18/PARC RNAi
- Alternative macrophage activation-associated CC chemokine 1
- AMAC1CC chemokine ligand 18
- AMAC-1Small-inducible cytokine A18
- chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated)
- DC-CK1CC chemokine PARC
- DCCK1Macrophage inflammatory protein 4
- Dendritic cell chemokine 1
- MIP-4C-C motif chemokine 18
- PARCPulmonary and activation-regulated chemokine
- SCYA18chemokine (C-C), dendritic
- small inducible cytokine A18
- small inducible cytokine subfamily A (Cys-Cys), member 18, pulmonary andactivation-regulated
Position of the Chimera RNAi. The related RNAi products listed were designed from different accesion number but sharing the same RNAi sequence. Chimera RNA interference (chimera RNAi) is process by which small interfering RNA/DNA chimera triggers the destruction of mRNA for the original gene. The discovery work, design, and application of chimera RNAi has been pioneered by Professor Kaoru Saigo and Dr. Kumiko Ui-Tei at the University of Tokyo. Chimera RNAi has many advantages over the conventional siRNAs. First, it has been demonstrated to have reliable knock-down for over 10,000 human genes. Because the human genome is composed of an intricate, genetic network, chimera RNAi's unique design has successfully obviated the off-target effects including microRNA-based influence. Another advantage of the chimera RNAi technology is its effectiveness at low concentrations (0.5nM to 5nM); only mRNA is destroyed so genomic genes are not affected. Finally, having both the sense and anti-sense strands consisting RNA/DNA chimera, it offers much greater compound stability for streamlining in vitro and in vivo assays and applications while minimizing interferon induction and other adverse reactions.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. RNAi are guaranteed
for 3 months from date of receipt.
Customers Who Viewed This Item Also Viewed...
Applications: WB, ICC/IF, IHC, IHC-P
Applications: WB, CyTOF-ready, ELISA(Cap), ELISA(Det), ICC, ICFlow, Neut, ELISA(Sta)
Species: Hu, Mu, Rt, Po, Bv, Eq
Applications: WB, ICC/IF, IHC
Species: Hu, Mu
Applications: WB, ICC/IF, IHC, IHC-P
Applications: RNAi, RNAi SP
Publications for CCL18/MIP4 RNAi (H00006362-R01) (0)
There are no publications for CCL18/MIP4 RNAi (H00006362-R01).
By submitting your publication information earn gift cards and discounts for future purchases.
Reviews for CCL18/MIP4 RNAi (H00006362-R01) (0)
There are no reviews for CCL18/MIP4 RNAi (H00006362-R01).
By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
- Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
- Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen
- 1st to review with an image -- $50/€35/£30/$50 CAD/¥300 Yuan/¥5000 Yen
FAQs for CCL18/MIP4 RNAi (H00006362-R01) (0)
Additional CCL18/PARC Products
Bioinformatics Tool for CCL18/MIP4 RNAi (H00006362-R01)
Discover related pathways, diseases and genes to CCL18/MIP4 RNAi (H00006362-R01). Need help?
Read the Bioinformatics Tool Guide
for instructions on using this tool.
PTMs for CCL18/MIP4 RNAi (H00006362-R01)
Learn more about PTMs related to CCL18/MIP4 RNAi (H00006362-R01).
Research Areas for CCL18/MIP4 RNAi (H00006362-R01)
Find related products by research area.
Blogs on CCL18/PARC